Newsfeeds - Spark Newswire

1 minute read

How To Attend Royalty Pharma Q1 2022 Earnings Conference Call

Today, 9:45 AM

Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to access the live webcast.

RPRX

6 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 27, 2022

By Benzinga Insights

Today, 9:45 AM

ACC

1 minute read

Goldman Sachs Initiates Coverage On Royalty Pharma with Buy Rating, Announces Price Target of $56

By Benzinga Newsdesk

Today, 9:45 AM

Goldman Sachs analyst Chris Shibutani initiates coverage on Royalty Pharma (NASDAQ:RPRX) with a Buy rating and announces Price Target of $56.

RPRX

1 minute read

Analyst Ratings

CORRECTION: JP Morgan Upgrades Royalty Pharma to Overweight, Announces Price Target of $50 – Earlier Posted with Incorrect Price Target

By Benzinga Newsdesk

Today, 9:45 AM

CORRECTION: JP Morgan analyst Chris Schott upgrades Royalty Pharma (NASDAQ:RPRX) from Neutral to Overweight and announces price target of $50 - earlier posted with incorrect price target.

RPRX

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 14, 2022

By Benzinga Insights

Today, 9:45 AM

Upgrades

ADYEY

1 minute read

JP Morgan Upgrades Royalty Pharma to Overweight, Announces Price Target Of $50

By Benzinga Newsdesk

Today, 9:45 AM

JP Morgan analyst Chris Schott upgrades Royalty Pharma (NASDAQ:RPRX) from Neutral to Overweight and announces price target of $50.

RPRX

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 6, 2022

By Benzinga Insights

Today, 9:45 AM

Upgrades

ABMD

1 minute read

Morgan Stanley Upgrades Royalty Pharma to Overweight, Raises Price Target to $48

By Benzinga Newsdesk

Today, 9:45 AM

Morgan Stanley analyst Terence Flynn upgrades Royalty Pharma (NASDAQ:RPRX) from Equal-Weight to Overweight and raises the price target from $46 to $48.

RPRX

2 minute read

Expedia And 3 Other Stocks Insiders Are Selling

By Lisa Levin

Today, 9:45 AM

Although gold futures traded lower on Thursday, there were a few notable insider trades.

EXPE

1 minute read

Royalty Pharma Q4 Sales $576.00M Beat $556.79M Estimate

By Benzinga Newsdesk

Today, 9:45 AM

Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $576.00 million which beat the analyst consensus estimate of $556.79 million by 3.45 percent. This is a 0.70 percent increase over sales of $572.00 million the

RPRX